Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter:
“Treatment for muscle invasive bladder cancer will change if the ongoing R3s are +ve. Neoadjuvant IO/ADC combination, bladder sparing approaches, intravesical therapy (TAR200) & ctDNA will improve outcomes and spare patients unnecessary treatments. This is the next chapter IMO.”
Source: Tom Powles/Twitter